CLK1 and neoplasm: SM08502 is an orally available pan-CLK/DYRK inhibitor that is effective at inhibiting multiple tumor types and has been demonstrated to inhibit WNT-mediated TCF activity (bioRxiv 2023.04.04.535570; refs. 11, 12).